Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer
- 3 February 2011
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 68 (4) , 897-904
Abstract
Purpose Adjuvant chemotherapy with cyclophosphamide (CYC) is used for the treatment of breast cancer. CYC is used as a racemic mixture, although preclinical data have demonstrated differences in the efficacy and toxicity of its enantiomers, with (S)-(-)-CYC exhibiting a higher therapeutic index. The present study investigated the enantioselectivity and influence of CYP2B6, CYP2C9, CYP2C19, and CYP3A on the kinetic disposition of CYC in patients with breast cancer. Methods Fifteen patients previously submitted to removal of the tumor and treated with racemic CYC (900 or 1,000 mg/m(2)) and epirubicin were included in the study. The in vivo activity of CYP3A was evaluated using midazolam as a marker drug. Serial blood samples were collected up to 24 h after administration of the first cycle of CYC. Results The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 mu g h/mL) due to the preferential clearance of the (R)-(+) CYC enantiomer (5.1 vs. 5.7 L/h). Clearance of either CYC enantiomer did not differ between the CYP2B6, CYP2C9, and CYP2C19 genotypes or as a function of the in vivo activity of CYP3A evaluated by midazolam clearance. Conclusions The pharmacokinetics of CYC is enantioselective in patients with breast cancer concomitantly treated with epirubicin and ondansetron. Genotyping or phenotyping did not contribute to adjustment of the CYC dose regimen in patients included in this study.Keywords
This publication has 30 references indexed in Scilit:
- DRUG FOCUS: Pharmacogenetic Studies Related to Cyclophosphamide-Based TherapyPharmacogenomics, 2009
- Determination of cyclophosphamide enantiomers in plasma by LC‐MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patientsChirality, 2008
- Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamidePharmacogenetics and Genomics, 2008
- Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patientsPharmacogenetics and Genomics, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer CohortJournal of Clinical Oncology, 2005
- A highly sensitive LC–MS–MS assay for analysis of midazolam and its major metabolite in human plasma: Applications to drug metabolismJournal of Chromatography B, 2005
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- Role of polymorphic human CYP2B6 in cyclophosphamide bioactivationThe Pharmacogenomics Journal, 2003
- A Single Nucleotide Polymorphism of CYP2B6 Found in Japanese Enhances Catalytic Activity by AutoactivationBiochemical and Biophysical Research Communications, 2001